

## HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF MONTELUKAST SODIUM AND LEVOCETIRIZINE DIHYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORMS

<sup>1</sup>NILAM K. PATEL, <sup>1</sup>SHIRISH PATEL, <sup>2</sup>S.S.PANCHOLI

<sup>1</sup>Department of Pharmaceutical Science, Hemchandracharya North Gujarat University, Patan, Gujarat, India, <sup>2</sup>Babariya Institute of Pharmacy, Gujarat Technological University, Baroda-391240, Gujarat, India. \*Email: nilamkpatel289@gmail.com

Received: 1 Nov 2011, Revised and Accepted: 29 Dec 2011

### ABSTRACT

A simple and precise HPLC method was developed for estimation of Montelukast sodium (MTKT) and Levocetirizine dihydrochloride (LCTZ) in pure and pharmaceutical dosage form. HPLC separation was achieved with a Phenomenex (Torrance, CA) C<sub>18</sub> column (250 mm × 4.6 mm id, 5 μm particle size) as stationary phase and methanol: Trichloroacetic acid: Acetonitrile (90:5:5, v/v/v) as eluent, at a flow rate of 1.0 ml/min. UV detection was performed at 231 nm. The retention time of Levocetirizine dihydrochloride and Montelukast sodium were found to be 2.4 and 3.5 min respectively. Results of the analysis were validated by recovery studies. The stability of Montelukast sodium was maintained by carrying out all the operations in amber colored glass wares with minimal exposure to light. The result of the studies showed that the proposed RP-HPLC method is simple, rapid, accurate & precise, which can be used for the routine determination of Montelukast sodium and Levocetirizine dihydrochloride in bulk and in its pharmaceutical dosage forms.

**Keywords:** Montelukast sodium, Levocetirizine dihydrochloride, HPLC, Assay, pharmaceutical dosage forms.

### INTRODUCTION

Montelukast sodium 2-[1-[(R)-[3-[2(E)-(7-chloroquinolin-2-yl) vinyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl) phenyl] propyl-sulfanylmethyl] cyclopropyl] acetic acid sodium salt (Figure 1) is a fast acting and potent cysteinyl leukotriene receptor antagonist which is being used in the treatment of asthma<sup>1</sup>. The recommended dosing of MTKT is 10mg per day. Levocetirizine (Figure 2) 2-[2-[4-[(R)-(4-chlorophenyl)-phenyl methyl] piperazinyl-1-yl]ethoxy] acetic acid, the R-enantiomer of racemic cetirizine, is a selective, potent, H<sub>1</sub>-antihistamine compound indicated for the treatment of allergic rhinitis and chronic idiopathic urticaria<sup>2</sup>. The LCTZ is official in IP-2007<sup>3</sup>. The recommended dosing of LCTZ is 5mg per day.




Fig. 1: Structure of Montelukast Sodium




Fig. 2: Structure of Levocetirizine dihydrochloride

Only a few chromatographic methods have been reported for the determination of MTKT and LCTZ, in individual and in combination with other drugs in the open literature. Liquid chromatography with fluorescence detection<sup>4-6</sup>, stereo selective HPLC for MTKT and its S-enantiomer<sup>7</sup>, simultaneous HPLC and derivative spectroscopic method with loratadine<sup>8</sup>, stability indicating HPLC method for MTKT

in tablets and human plasma<sup>9</sup> reported for MTKT. Different spectrophotometric<sup>10</sup>, HPLC<sup>11-15</sup> and LCMS<sup>16,17</sup> methods have been reported for the determination of cetirizine in pharmaceutical formulations and biological fluids.

During our literature survey, simple RP-HPLC, HPTLC and ratio derivative spectroscopy for determination of MTKT and LCTZ was found.<sup>18-22</sup> The reported simple RP-HPLC method used phosphate buffer (pH adjusted to 5.5 with dil. KOH): Acetonitrile (65:35, v/v) as a mobile phase. The goal of this study was to develop a method without using buffer in a mobile phase, has a less run time, and more sensitive compare to developed method for the analysis of Montelukast and Levocetirizine in formulations, using the most commonly employed C-18 column with UV detection and extremely low LOQ & LOD values.

The objective of this work was to develop and validate an accurate, specific, precise, repeatable, HPLC method for determination of MTKT and LCTZ in combination dosage forms.

### MATERIALS AND METHODS

#### Instruments and Apparatus

The chromatography was performed on a Shimadzu (Columbia, MD) RP-HPLC instrument (LC-2010CHT) equipped with PDA detector and LC-solution software, Phenomenex (Torrance, CA) C<sub>18</sub> column (250×4.6 mm id, 5 μm particle size) was used as stationary phase. Sartorius CP224S analytical balance (Gottingen, Germany) and ultrasonic cleaner (Frontline FS 4, Mumbai, India) were used during the research work.

#### Reagents and materials

Standard samples of MTKT and LCTZ were obtained from Cedilla Healthcare Ltd, Ahmedabad. Triple distilled water, methanol, acetonitrile, Trichloroacetic acid (S. D. Fine Chemicals) used were of HPLC grade.

#### Preparation of Standard Solution

Accurately weighed MTKT (100 mg) and LCTZ (100 mg) standards were transferred to a 100 ml volumetric flask, dissolved in and diluted up to the mark with methanol to obtain a standard stock solution (1000 μg/ml) of MTKT and LCTZ, each. From the above stock solution, an aliquot (5 ml) of the solution was transferred to 50 ml volumetric flask, and diluted up to the mark with methanol to obtain a working standard solution (100 μg/ml) of MTKT and LCTZ, each.

### Preparation of Calibration Curve

Calibration curves were plotted over the concentration range of 0.5-30 µg/ml of MTKT and LCTZ. Accurately prepared standard solution of MTKT and LCTZ (0.05, 0.1, 0.5, 1, 1.5, 2, 2.5, and 3 ml) were transferred in 10ml volumetric flask and diluted with mark by using mobile phase. The calibration curves were constructed by plotting peak areas versus concentrations. An aliquot (10 µl) of each solution was injected under the operating chromatographic conditions as described above and responses were recorded. Calibration curves were constructed by plotting the peak areas versus the concentrations, and the regression equations were calculated. Each response was average of three determinations.

### Preparation of Sample Solution

Twenty tablets were weighed and powdered. The quantity of the powder equivalent to 10 mg of MTKT and 5 mg of LCTZ was transferred to a 100 ml volumetric flask. The content was mixed with methanol (100 ml), sonicated for 20 min. to dissolve the drug as completely as possible. The solution was then filtering through a whatman filter paper no. 41. The volume was adjusted up to the mark with methanol. An aliquot (0.5ml) was transferred to a 10 ml

volumetric flask and diluted up to the mark with mobile phase used for HPLC, to obtain sample solution of MTKT (5 µg/ml) and LCTZ (2.5 µg/ml).

## RESULTS AND DISCUSSION

### Method Development

Initially various mobile phases were tried in attempt to obtain the best separation and resolution between Montelukast and Levocetirizine. The mobile phase of Methanol: Trichloroacetic acid: Acetonitril (90:5:5, v/v/v) was found to be an appropriate mobile phase allowing the adequate separation of both the compounds using a Phenomenex (Torrance, CA) C<sub>18</sub> column (250 mm × 4.6 mm id, 5 µm particle size), at a flow rate of 1.0ml/min. a typical chromatogram of separation of the two components is shown in figure 3. As the MTKT and LCTZ exhibit significant absorbance at wavelength 231nm, it was selected as detection wavelength for the simultaneous determination of MTKT and LCTZ in pharmaceutical dosage forms. The retention time of LCTZ and MTKT were found to be 2.4 and 3.5 respectively. The resolution, theoretical plate and tailing factors are prescribed in table.1.




Fig. 3: HPLC spectra of Montelukast Sodium and Levocetirizine Dihydrochloride

Table 1: System Suitability Parameters

Parameters	MTKT ± RSD (n = 6)	LCTZ ± RSD (n = 6)
Retention time (min)	3.5 ± 0.29	2.4 ± 0.15
Tailing factor	1.25 ± 0.26	1.19 ± 0.20
Theoretical plates	4085 ± 0.35	3548 ± 0.39
Resolution	4.72 ± 0.19	

### Validation of the Method

The retention time for LCTZ and MTKT was found to be 2.4 and 3.5 minutes respectively. For the evaluation of linearity, different concentrations of standard solution were prepared in the concentration range of 0.5-30 µg/mL for LCTZ and MTKT with correlation of 0.9965 for LCTZ and 0.9956 for MTKT. Accuracy of the method was ascertained by recovery study (n=3) (table 2). The concentration of the standard spiked to the sample was 50-150 % of the assay level. The method was found to be accurate with percent recoveries between 98.27% - 99.03% with standard deviation not

more than 1.14 for LCTZ and recoveries between 98.12% - 99.04% with standard deviation not more than 0.71 for MTKT. There was good repeatability of proposed method with percentage RSD 0.373 for LCTZ and 0.305 for MTKT. The limit of detection (LOD) and limit of quantification (LOQ) of LCTZ were found to be 0.22µg/ml and 0.56µg/ml respectively. The limit of detection (LOD) and limit of quantification (LOQ) of MTKT were found to be 0.32µg/ml and 0.72µg/ml respectively. The result of specificity studies indicated no interference from excipients and mobile phase. The response was due to individual components only. All validation parameters were summarized in table 3.

Table 2: Recovery Studies

Drug	Tablet amount(µg/ml)	Amount added (µg/ml)	Amount recovered (µg/ml)*	Recovery	Coefficient of variation
LCTZ	1	0.5	0.491	98.27	0.667
	1	1	0.988	98.84	1.145
	1	1.5	1.485	99.03	0.836
MTKT	2	1	0.982	98.21	0.644
	2	2	1.980	99.04	0.711
	2	3	2.943	98.12	0.214

\*Each value is the mean of three determinations.

**Table 3: Summary of validation Parameters of Proposed HPLC method**

Parameters	MTKT	LCTZ
Range (µg/ml)	0.5-30	0.5-30
Regression equation $y=mx+c$	$Y = 580542x + 84143$	$Y = 502448x + 62869$
Slope	580542	502448
Intercept	84143	62869
Correlation coefficient (r)	0.9956	0.9965
LOD (µg/ml)	0.32	0.22
LOQ (µg/ml)	0.72	0.56
%Recovery ± SD, (n=3)	98.46± 0.52	98.71±0.89
Repeatability (%RSD, n=6),	0.30	0.37
Interday precision (%RSD) (n = 3) at 3 range	0.53-1.02	0.59-1.12
Intraday precision (%RSD) (n = 3) at 3 range	0.32-0.50	0.45-0.51
% assay ± SD (n= 6)	98.80±0.40	99.16±0.89

<sup>a</sup>SD = Standard deviation, <sup>b</sup>RSD = Relative standard deviation

#### Analysis of LCTZ and MTKT in Formulation

The LCTZ and MTKT content were found to be 99.16±0.89 % and 98.80±0.407 respectively, of the label claim. The low value of % RSD indicated the method was suitable for routine analysis of the MTKT and LCTZ in pharmaceutical dosage forms. Result of assay was summarizing in table 4.

**Table 4 : Assay Result**

Dosage form	Drug	Label claim (mg)	Percent Label claim estimated*(Mean±SD)
Tablet	MTKT	10 mg	98.80± 0.407
	LCTZ	5 mg	99.163± 0.895

\*Indicate average of six determination and SD denotes standard deviation

#### CONCLUSION

The proposed, the developed HPLC method is simple, liner, accurate, sensitive and reproducible. Thus, the developed method can be easily used for the routine quality control of bulk and tablet dosage form of Levocetirizine and Montelukast within a short analysis.

#### ACKNOWLEDGMENT

All authors are greatly thankful to S K Patel College of Pharmaceutical Education and Research, Ganpat vidyanagar, kherva-382711 for providing facilities to carry out the work.

#### REFERENCE

- Budavari S, editor: The Merck Index. 12th ed. Whitehouse Station, NJ: Merck & Co Inc; 1996. 1070.
- Sweetman, S.C., Martindale, the Extra pharmacopoeia, 34th ed. London: pharmaceutical press. 2004; 435.3: 11.
- Indian Pharmacopoeia, Vol. II, Government of India, The controller of Publication, New Delhi. 2007; 1290.
- Al-Rawithi S, Al-Gazlan S, Al-Ahmadi W, Alshowaier I, Yusuf A, Raines D. Expedient liquid chromatographic method with fluorescence detection for Montelukast sodium in microsamples of plasma. J Chromatogram B Biomed Sci Appl. 2001; 754:527-31.
- Ochiai H, Uchiyama N, Takano T, Hara K, Kamei T. Determination of Montelukast sodium in human plasma by column-switching high performance liquid chromatography with fluorescence detection. J Chromatogram B Biomed Appl. 1998; 713: 409-14.
- Chauhan B, Shubha Rani, Nivsarkar M, Padh H. New liquid liquid extraction method for determination of Montelukast in small volume human plasma samples using HPLC with fluorescence detector. Indian J Pharm Sci. 2006; 68:517-20.
- Liu L, Cheng H, Zhao JJ, Rogers JD. Determination of Montelukast (MK-0476) and S-enantiomer in human plasma by stereoselective high performance liquid chromatography with column switching. J Pharm Biomed Anal. 1997; 15:631
- Radhakrishna T, Narasaraju A, Ramakrishna M, Satyanarayana A. Simultaneous determination of Montelukast and Loratadine by HPLC and derivative Spectrophotometric methods. J Pharm Biomed Anal. 2003; 31:359-68
- Alsarra I. Development of a stability-indicating HPLC method for the determination of Montelukast in tablets and human plasma and its applications to pharmacokinetic and stability studies. Saudi Pharm J. 2004; 12:136-43
- A.F.M. El Walily, et al. Spectrophotometric and high performance liquid chromatographic determination of cetirizine dihydrochloride in pharmaceutical tablets. J. Pharmaceut. Biomed. Anal. 1998, 17: 435-442.
- Sevgi K, et al. Development and validation of a rapid RP-HPLC method for the determination of cetirizine or fexofenadine with pseudoephedrine in binary pharmaceutical dosage forms. J. Pharmaceut. Biomed. Anal. 2008, 46: 295-302
- Sun Ok Choi, et al. Stereoselective determination of cetirizine and studies on pharmacokinetics in rat plasma. Journal of Chromatography B. 2000, 744: 201-206.
- Mee-Kyung Kim, et al. Narrow-bore high performance liquid chromatographic method for the determination of cetirizine in human plasma using column switching. J. Pharmaceut. Biomed. Anal. 2005, 37:603-609
- Jabera A.M.Y., et al. Determination of cetirizine dihydrochloride, related impurities and preservatives in oral solution and tablet dosage forms using HPLC. J. Pharmaceut. Biomed. Anal. 2004, 36:341-350
- Raghad Hommos, et al. Determination of Levocetirizine configurational stability in tablets using chiral HPLC method. IJPPS, 2011, 3(2):103-07
- Melanie M.T., et al. Automated 96-well solid phase extraction and hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the analysis of cetirizine in human plasma—with emphasis on method ruggedness. Journal of Chromatography B, 2005, 814:105-11
- Mortia M.R, et al. Determination of Levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: Application to a bioequivalence study. Journal of chromatography B. 2008, 862:132-139
- Sharma Smita, Sharma M. C, Kohli D.V, Sharma A.D. Development and Validation of TLC Densitometry Method for Simultaneous quantification of Montelukast Sodium and Levocetirizine dihydrochloride Pharmaceutical Solid Dosage Form, Scholars Research Library, Der Pharmacia Lettre, 2010; 2(1): 489-494.
- Choudhari V, Kale A, Abnawe S, Kuchekar B, Gawli V, Patil N. Simultaneous Determination of Montelukast Sodium and Levocetirizine dihydrochloride in Pharmaceutical Preparations by Ratio Derivative Spectroscopy. IJPRIF, 2010; 2(1):04-09
- Rathore Atul S, Sathiyarayanan L and Mahadik K.R. Development of Validated HPLC and HPTLC Methods for Simultaneous Determination of Levocetirizine dihydrochloride and Montelukast Sodium in Bulk Drug and Pharmaceutical Dosage Form. Pharmaceutica Analytica Acta, 1(1):1000106.
- Ashokkumar S, Raja Senthil M, Perumal P. RP-HPLC Method Development and Validation for Simultaneous Estimation of Montelukast sodium and Levocetirizine dihydrochloride. International Journal of Pharmaceutical Research. 2009; 1(4): 8-12.
- Kamyar Pourghazi, et al. Spectrophotometric determination of cetirizine and Montelukast in prepared formulation. IJPPS, 2011, 3(2):128-30

